联控(03396.HK)旗下联泓新科於深交所中小板挂牌
联想控股(03396.HK)旗下联泓新科(003022.SZ)在深交所中小板挂牌交易。联泓新科是次公开发行逾1.47亿股,每股发行价11.46元人民币(下同),挂牌首日股价最高升44%至16.5元,市值169.5亿元。上市後,联想控股持有附属联泓新科股权比例为51.77%。
联泓新科为从事先进高分子材料及特种精细材料的研发、生产与销售的高新技术企业。根据招股书显示,2017年、2018年、2019年及2020年首九个月,联泓新科净利润分别为5,519.72万元、2.29亿元、5.32亿元和4.23亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.